SCHEMBL18378102

SCHEMBL18378102

O=C(Nc1cccc(Br)c1)c1cccc(F)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.72
MEN1 O00255 4/20 0.72
KCNK3 O14649 2/20 0.72
NPC1 O15118 4/20 0.67
RAB9A P51151 4/20 0.67
HPGD P15428 1/20 0.67
KCNK9 Q9NPC2 1/20 0.67
KDM4E B2RXH2 1/20 0.62
CASP3 P42574 1/20 0.62
SENP7 Q9BQF6 1/20 0.62
SENP6 Q9GZR1 1/20 0.62
L3MBTL1 Q9Y468 2/20 0.61
HDAC1 Q13547 1/20 0.60
HDAC6 Q9UBN7 1/20 0.60
SMN1; SMN2 Q16637 4/20 0.59
ALDH1A1 P00352 1/20 0.59
NFKB1 P19838 1/20 0.58
HTT P42858 1/20 0.58
NFKB2 Q00653 1/20 0.58
RELA Q04206 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4258383 0.94 NPC1 (0.71) KMT2AMEN1KCNK3NPC1RAB9A
SCHEMBL29817846 0.94 NPC1 (0.71) KMT2AMEN1KCNK3NPC1RAB9A
SCHEMBL3670066 0.89 SMN1; SMN2 (0.72) KMT2AMEN1KCNK3NPC1RAB9A
SCHEMBL148104 0.86 MEN1 (0.78) KMT2AMEN1KCNK3NPC1RAB9A
SCHEMBL22191811 0.83 MEN1 (0.78) KMT2AMEN1KCNK3NPC1RAB9A
SCHEMBL6027951 0.83 MEN1 (0.88) KMT2AMEN1KCNK3NPC1RAB9A
SCHEMBL30643220 0.83 MEN1 (0.88) KMT2AMEN1KCNK3NPC1RAB9A
SCHEMBL1811680 0.83 L3MBTL1 (0.82) KMT2AMEN1KCNK3NPC1RAB9A
SCHEMBL22574392 0.82 MEN1 (0.59) KMT2AMEN1KCNK3NPC1RAB9A
SCHEMBL19156946 0.81 KCNK3 (0.79) KMT2AMEN1KCNK3NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106132951-B quinoline-based kinase inhibitors 百时美施贵宝公司 2019-02-12 CN disclosed
EP-3099673-B1 QUINOLINE-BASED KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-09-26 EP disclosed
US-9932320-B2 Quinoline-based kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-04-03 US disclosed
US-20160332985-A1 Quinoline-Based Kinase Inhibitors BRISTOL-MEYERS SQUIBB COMPANY (US) 2016-11-17 US disclosed
CN-106132951-A Quinoline-based kinase inhibitors 百时美施贵宝公司 2016-11-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332985-A1 Quinoline-Based Kinase Inhibitors AAK1, EEF2K, ADCK1 KMT2A 2221/4885MEN1 4189/4885KCNK3 1275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.